@vdieriks.bsky.social
Neuroscientist focusing on Parkinson’s disease and multiple system atrophy. Group leader Synuclein Lab at the University of Auckland, New Zealand, love hiking, trail running and watching sunsets. Dierikslab.com
Our work on MSA in the news.
www.nzherald.co.nz/nz/groundbre...
In a new paper, researchers present a refinement of the RT-QuIC protocol & analysis pipeline that can distinguish between #Parkinsons & #MSA, plus between MSA phenotypes
translationalneurodegeneration.biomedcentral.com/articles/10....
Tonga, Samoa and Guam
07.02.2025 07:29 — 👍 0 🔁 0 💬 0 📌 0🧠🌍 Quiz Time!
Take a close look at this image: 🗺️
❓ Can you name these three countries?
Hint: They share a surprising connection to Parkinson's disease.
Drop your answers below and let's discuss! 🧬🗨️
#Parkinsons #HealthQuiz
Happy New year everyone! Let make 2025 a good one!! #newyear
31.12.2024 12:20 — 👍 1 🔁 0 💬 0 📌 0I’m on holiday but want to share our latest published work on alpha synuclein, before I get beaten to it by @scienceofpd.bsky.social I will post the highlights in the new year. Even is you do not do PD research, I recommend looking at it for the amazing images!! rdcu.be/d4Vzd
27.12.2024 04:43 — 👍 0 🔁 0 💬 0 📌 04/4 A huge thanks to our team and collaborators for their hard work and dedication! This advancement could pave the way for a better understanding of Parkinson's early on. Stay tuned for more updates!
Thanks to our funders
HRCNewZealand
FMHS_UoA
AucklandUni
NeurologicalNZ
AMRF
CHIER protocol
3/4 We've pioneered a new antigen retrieval protocol: 'Cyclic Heat-Induced Epitope Retrieval (CHIER).' This innovative method significantly boosts the detection of SMARCC2 cytobodies, without compromising the integrity of other epitopes. 🧪🔬
19.12.2024 05:12 — 👍 1 🔁 0 💬 1 📌 0SMARCC2 Cytobodies
2/4 SMARCC2, known for its role in chromatin remodelling and transcription regulation, forms unique honeycomb-structured cytobodies in neurons. Our findings show an increase in these cytobodies in Parkinson's Disease, suggesting a potential role in early disease progression.
19.12.2024 05:12 — 👍 1 🔁 0 💬 1 📌 0🎉 Excited to share our latest work: "Enhanced detection of distinct honeycomb-structured neuronal SMARCC2 cytobodies in Parkinson’s Disease via Cyclic Heat-Induced Epitope Retrieval (CHIER)." Two key insights in this thread! 🧵 1/4
journals.plos.org/plosone/arti...
Thanks to my PhD students JamesAWiseman and KreesanReddy for all their work, and the invaluable support from mentors and funders (HRCNewZealand, FMHS_UoA, AucklandUni, NeurologicalNZ, AMRF and MedtechNZ) dierikslab.com
16.12.2024 03:31 — 👍 1 🔁 0 💬 0 📌 0Understanding this balance and its timing is crucial, as it may determine the severity of different α-synucleinopathies. Incorporating this knowledge into future studies is vital.
16.12.2024 03:31 — 👍 0 🔁 0 💬 1 📌 0The diversity in α-Syn strains, truncations, and post-translational modifications contributes to the variability observed in these disorders. The critical point at which α-Syn aggregation shifts from a consequence to a driving force in disease progression remains unknown.
16.12.2024 03:31 — 👍 0 🔁 0 💬 1 📌 0The initiation of α-Synuclein (α-Syn) aggregation appears to be triggered by disease factors—both genetic and environmental. In genetic forms of Parkinson's Disease (PD) and atypical α-synucleinopathies, this interplay is complex.
16.12.2024 03:31 — 👍 0 🔁 0 💬 1 📌 0How can a single protein orchestrate a vast array of diseases from early development to advanced age?
16.12.2024 03:31 — 👍 0 🔁 0 💬 1 📌 0I'm excited to share our latest manuscript: "From Onset to Advancement: The Temporal Spectrum of Alpha-Synuclein in Synucleinopathies." in Aging Research Reviews. A thread:
sciencedirect.com/science/arti...
We asked one question:
Keen to connect with others and discover breakthrough research on Bluesky. My focus is on #Parkinson’sDisease, #MSA, #Synuclein
16.12.2024 02:25 — 👍 1 🔁 0 💬 0 📌 0Can I get added please?
16.12.2024 02:22 — 👍 1 🔁 0 💬 1 📌 0